Abstract: The present invention relates to a lithium metal oxide having a nickel oxide layer formed on a surface thereof, and represented by Formula 1; and the lithium metal oxide can be prepared by a method of preparing a lithium metal oxide having a nickel oxide layer formed on a surface thereof, the method comprising steps of: (1) complexing a nickel precursor onto a surface of a lithium metal oxide; and (2) calcining, through a heat treatment, the lithium metal oxide—the surface of which is complexed with the nickel precursor—obtained in Step (1).

Abstract: Disclosed are a data concealment apparatus and a data concealment method using an Error Correction Code. According to exemplary embodiments of the present invention, it is possible to prevent important information from being easily exposed to a third person by generating encoding data through convolution encoding of input data and thereafter, concealing the encoding data on an image through adjustment of a pixel value on the image and minimize an error which can occur at the time of recovering the input data by extracting the encoding data from the image in a soft decision scheme and performing Viterbi-decoding on the extracted encoding data in order to recover the input data concealed in the image.

Abstract: A multi-grid method using a V cycle includes: obtaining a first intermediate solution and a first residual by smoothing a cell of a fine level; obtaining a cell of a coarse level by down-sampling the cell of the fine level and setting the first residual as a second residual of the cell of the coarse level; obtaining a high-frequency component solution of the cell of the fine level and obtaining a smoothed high-frequency component solution by smoothing the high-frequency component solution; obtaining a coarse solution in the cell of the coarse level; up-sampling and transferring the coarse solution to the cell of the fine level and obtaining a corrected intermediate solution by adding the first intermediate solution, the smoothed high-frequency component solution and the coarse solution; and obtaining a second intermediate solution by smoothing the corrected intermediate solution.

Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.

Abstract: The present invention provides a radio frequency identification (RFID)-integrated self-powered time-temperature integrator (TTI), which comprises an RFID and a self-powered TTI which is attached to the exterior of a package of food to output an electric signal indicating a storage state of the food and supplies the electric signal as an operating power of the RFID, in which the electric signal output from the self-powered TTI is a voltage corresponding to a rate of a change in quality of the food accompanied, the quality is calculated by an integration value of time-voltage, and an integration algorithm uses an integrated value, obtained by adding the voltage measured every hour, as a quality variable of the food.

Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Abstract: The present invention relates to a CT contrast agent for detecting a thrombus, comprising fibrin-targeted peptide sequence-conjugated glycol chitosan-gold nanoparticles. The CT contrast agent for detecting a thrombus according to an embodiment of the present invention may allow rapid and repeated acquisition of CT image information related to the size and location of a thrombus in cardio-cerebral vascular thrombosis, and also enables the imaging monitoring of cerebral thrombus.

Abstract: The present invention relates to a method for manufacturing a transistor according selective printing of a dopant. For the manufacture of a transistor, a semiconductor layer is formed on a substrate, and a dopant layer is formed on the semiconductor layer. In the formation of the dopant layer, an inkjet printing is used to selectively print an n type dopant or a p type dopant.

Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

Abstract: The present invention relates to a method of differentiating mesenchymal stem cells or adult stem cells into nerve cells by treating the mesenchymal stem cells or the adult stem cells with an electromagnetic field having a high intensity of 100 to 1,500 mT and a low frequency of 0.01 to 100 Hz. The present invention also relates to a medical device to which the method is applied. The method of differentiating nerve cells by using a magnetic field, and a composition according to the present invention induce the differentiation of adult stem cells into nerve cells by using a low-frequency, high-intensity electromagnetic field, so that nerve cells or neural stem cells can easily be differentiated through only electromagnetic field treatment in a short time.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation.

Abstract: Disclosed are 4-substituted-2-(5-substituted-1H-indol-2-yl)phenol derivatives for controlling the proliferation and migration of kinase-overexpressed cells. The phenol derivatives are represented by Formula 1: wherein X is selected from the group consisting of hydrogen, halogen, a cyano group, a trifluoromethyl (CF3) group, an amidine (C(?NH)NH2) group, and a 5-methyl-1,2,4-oxadiazole group, Y is selected from the group consisting of hydrogen, halogen, a phenyl group substituted with one or two substituents selected from the group consisting of halogen, methoxy, nitro, trifluoromethyl, and aminomethyl, CO—R?, COOR?, OH, O—R?, and NH—R?, each R? is independently selected from the group consisting of C1-C18 alkyl, alkenyl, alkynyl, and —Z-alkyl (wherein Z is a heteroatom selected from the group consisting of O, S, and N or is —(CH2)m—), and m is an integer from 0 to 5.

Abstract: The present invention relates to a composition for preventing, treating or alleviating atopic dermatitis comprising an immunosuppressant and a transglutaminase 2 inhibitor as active ingredients. Conjoint administration of an immunosuppressant and a transglutaminase 2 inhibitor according to the present invention makes it possible to achieve far better therapeutic effects than with administration of either an immunosuppressant or a transglutaminase 2 inhibitor alone, since there is a reduction in the dose of an immunosuppressant which is difficult to administer for a long time because of side effects and with which, when discontinued, lesions are liable to become exacerbated to the original state, and since an immunosuppressant is mixed with a transglutaminase 2 inhibitor which in some patients has a lackluster effect in treating atopic dermatitis.

Abstract: A method and apparatus for transmitting a training sequence code of a transmitting apparatus with a plurality of transmitting antennas in a communication system are provided. A transmitting apparatus allocates a plurality of time slots for the plurality of transmitting antennas to be divided into at least one frame, and sends a training sequence code with reference power for any one of the transmitting antennas, and sends remaining training sequence codes for remainders of the transmitting antennas with transmission power from zero to the reference power, in any one of the time slots. A receiving apparatus receives a plurality of training sequence codes for a plurality of transmitting antennas through any one of the plurality of receiving antennas from a transmitting apparatus, and selects one of the training sequence codes having the greatest reception power to estimate a channel. This may improve a channel estimation performance in a communication system.

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic fatty liver.

Abstract: Provided are a ramp signal calibration apparatus and method and image sensor including the apparatus. The apparatus includes: an analog-to-digital converter (ADC) including a trimmable transistor having a gain value that varies according to stored data, and configured to receive a ramp signal in a state where the gain value is a first gain value, and to output first and second output signals; a subtractor configured to calculate a difference between the first and second output signals; a digital comparator configured to compare the difference with a reference value and to determine whether a slope of the ramp signal has changed; and a counter configured to change the stored data based on whether the slope of the ramp signal has changed, wherein when the counter changes the data, the first gain value of the trimmable transistor is changed to a second gain value according to the changed data.

Abstract: The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases.

Abstract: An image sensor may include a comparator including a first input terminal configured to receive a reset signal, a second input terminal configured to receive an image signal, a third input terminal configured to receive a ramp signal configured to ramp in one direction, and an output terminal. The comparator may further include a switch circuit including a plurality of switches. The comparator may be configured to compare the reset signal with the ramp signal and output a first comparison signal through the output terminal according to a first arrangement of the switches in a reset phase and the comparator may be configured to compare the image signal with the ramp signal and output a second comparison signal through the output terminal according to a second arrangement of the switches in an image phase.

Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

Abstract: The present invention relates to a two-dimensional code-type time-temperature indicator the color or shape of which changes in accordance with time and temperature conditions, and to a method for manufacturing the time-temperature indicator, to a quality guarantee system using the time-temperature indicator, and to a quality guarantee method using the quality guarantee system. The time-temperature indicator comprises: nanobeads containing a microorganism for generating lactic acids using nutrient components, an indicating agent for indicating the change in color by means of the generated lactic acids, an immobilization material for immobilizing the microorganism, the indicating agent, and the nutrient components; a base having a bonding layer; and a cover film.